Zhou Yan, Zhang Guo-Qiang, Wei Yu-Hui, Zhang Jian-Ping, Zhang Guo-Rong, Ren Jiang-Xia, Duan Hao-Gang, Rao Zhi, Wu Xin-An
Department of Pharmacy, First Hospital of Lanzhou University, Lanzhou, 730000, China.
Eur J Drug Metab Pharmacokinet. 2013 Jun;38(2):77-85. doi: 10.1007/s13318-013-0117-1. Epub 2013 Jan 22.
In this review, we have highlighted the adverse drug reaction mediated by transporters from two aspects: (1) competitive interactions between drug and drug/metabolite/endogenous substance mediated by transporters; (2) the expression/function change of transporter due to physiologic factors, disease, and drugs induction. It indicated that transporters exhibited a broad substrate specificity with a degree of overlap, which could change the pharmacokinetics of drugs and cause toxicity due to competition interactions among substrates. In addition, the expression and function of transporters were regulated by physiological conditions, pathological conditions, and drugs induction, which could cause adverse drug reaction and interindividual differences. Furthermore, one substrate was always medicated by several transporters and often subjected to metabolism by CYP enzymes, so we should be more aware of the increased plasma concentration of drugs caused by drug transporters as well as drug metabolizing enzymes synergistically, especially for drugs with narrow therapeutic window. In addition, the weightiness for one transporter to induce drugs plasma/tissue concentration change could be different in different condition. On the whole, transporters were corresponding with systemic/organs exposure of drug/metabolites/endogenous compounds. So understanding the expression and function in drug transporters will result in better strategies for optimal dosage regimen and reduce the risk for drug adverse reaction as well as adverse drug-drug interactions.
在本综述中,我们从两个方面强调了转运体介导的药物不良反应:(1)转运体介导的药物与药物/代谢物/内源性物质之间的竞争性相互作用;(2)生理因素、疾病和药物诱导导致的转运体表达/功能变化。结果表明,转运体表现出广泛的底物特异性且存在一定程度的重叠,这可能会改变药物的药代动力学,并由于底物之间的竞争相互作用而导致毒性。此外,转运体的表达和功能受生理状况、病理状况和药物诱导的调节,这可能会导致药物不良反应和个体差异。此外,一种底物通常由多种转运体介导,并且常常受到细胞色素P450酶的代谢作用,因此我们应该更加关注药物转运体以及药物代谢酶协同作用导致的药物血浆浓度升高,尤其是对于治疗窗较窄的药物。此外,在不同情况下,一种转运体对药物血浆/组织浓度变化的影响程度可能不同。总体而言,转运体与药物/代谢物/内源性化合物的全身/器官暴露相关。因此,了解药物转运体的表达和功能将有助于制定更好的优化给药方案策略,并降低药物不良反应以及药物相互作用的风险。